

Results of Phase 1b Fludrocortisone Study Featured at 2022 RANZCO Congress

The results of the Phase 1b safety study for Eye Co's lead compound *fludrocortisone acetate*, featured as a poster in the **Royal Australian and New Zealand College of Ophthalmology** (RANZCO) Annual Scientific Congress in Brisbane this month. A version of the poster is provided separately.

The results of this study were also published in the British Medical Journal in July 2022 and demonstrated that this compound did not have any of the side effects commonly associated with products indicated for the treatment of retinal diseases such as a rise in intraocular pressure or cataract formation.

Peter Abrahamson

3 November 2022